15,382 Shares in Qiagen N.V. $QGEN Acquired by Shelton Capital Management

Shelton Capital Management bought a new stake in shares of Qiagen N.V. (NYSE:QGEN) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 15,382 shares of the company’s stock, valued at approximately $739,000.

Several other large investors also recently made changes to their positions in QGEN. Wellington Management Group LLP boosted its position in shares of Qiagen by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock worth $972,191,000 after buying an additional 2,656,136 shares during the period. Deutsche Bank AG raised its stake in Qiagen by 57.5% during the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock valued at $180,319,000 after acquiring an additional 1,639,621 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Qiagen by 3,030.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock worth $179,501,000 after acquiring an additional 4,327,934 shares during the period. Norges Bank acquired a new position in Qiagen during the 2nd quarter worth $158,728,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Qiagen by 11.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,732,963 shares of the company’s stock worth $131,756,000 after purchasing an additional 287,322 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. UBS Group boosted their price target on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Barclays set a $53.00 price objective on shares of Qiagen and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday. Three investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average target price of $49.69.

Qiagen Stock Performance

Shares of QGEN opened at $46.94 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The firm’s 50 day moving average is $46.35 and its 200-day moving average is $46.94. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The stock has a market capitalization of $10.43 billion, a P/E ratio of 27.73, a P/E/G ratio of 2.48 and a beta of 0.64.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03. The business had revenue of $532.58 million during the quarter, compared to analyst estimates of $525.68 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.57 earnings per share. Equities research analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.